Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma
ConditionNewly Diagnosed Glioblastoma
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorSwedish Medical Center
About this trial
Proposed treatment of subjects with newly diagnosed glioblastoma with novel personalized drug regimens identified to be effective in vitro using cancer stem cells derived from their individual tumors, alongside standard of care radiation and TMZ.
Eligibility criteria
Qualifiers
Histological diagnosis of GBM (WHO grade 4)
Subjects ≥18 years of age
Patients must have a life expectancy of >6 months
Patients must have a surgically accessible tumor with the intent for a gross or near total resection of the tumor mass (GBM, WHO grade 4)
Disqualifiers
Metastatic disease
Diseases or conditions that obscure toxicity or dangerously alter drug metabolism
Serious intercurrent medical illness
Inadequately controlled hypertension
Trial design
Treatments tested in this trial
- combinations of up to 3 FDA approved drugs from a panel of compounds
Treatment groups
10 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov